Twist Bioscience Corp

For the period ended Mar 31, 2025. Filed May 5, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 5, 2025

TWST$132.13-2.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity (unaudited)

Commonstock · Additional paid-incapital · Accumulated Othercomprehensiveloss · Accumulateddeficit · Totalstockholders'equity
(In thousands) · Shares · Amount
Balances as of December 31, 2024	59,582	$—		$1,730,092		$(649)		$(1,273,502)	$455,941
Restricted common stock canceled	(137)	$—		$—		$—		$—	$—
Vesting of restricted stock units	275	—	—		—	—	—
Exercise of stock options	72	—	771		—	—	771
Issuance of shares under the employee stock purchase plan	65	—	2,429		—	—	2,429
Repurchases of common stock for income tax withholding	—	—	(4)		—	—	(4)
Stock-based compensation	—	—	20,312		—	—	20,312
Other comprehensive loss	—	—	—		(13)	—	(13)
Net loss	—	—	—		—	(39,328)	(39,328)
Balances as of March 31, 2025	59,857	$—		$1,753,600		$(662)		$(1,312,830)	$440,108

Commonstock · Additional paid-incapital · Accumulated Othercomprehensiveincome · Accumulateddeficit · Totalstockholders'equity
(In thousands) · Shares · Amount
Balances as of December 31, 2023	57,779	$—		$1,666,797		$(565)		$(1,076,190)	$590,042
Vesting of restricted stock units	229	$—		$—		$—		$—	$—
Exercise of stock options	69	—	1,317		—	—	1,317
Issuance of shares under the employee stock purchase plan	124	—	2,047		—	—	2,047
Repurchases of common stock for income tax withholding	(39)	—	(1,535)		—	—	(1,535)
Stock-based compensation	—	—	13,847		—	—	13,847
Other comprehensive loss	—	—	—		(95)	—	(95)
Net loss	—	—	—		—	(45,492)	(45,492)
Balances as of March 31, 2024	58,162	$—		$1,682,473		$(660)		$(1,121,682)	$560,131

Commonstock · Additional paid-incapital · Accumulated Othercomprehensiveincome · Accumulateddeficit · Totalstockholders'equity
(In thousands) · Shares · Amount
Balances as of September 30, 2024	58,877	$—		$1,715,119		$(522)		$(1,241,908)	$472,689
Restricted common stock canceled	(137)	$—		$—		$—		$—	$—
Vesting of restricted stock units	811	—	—		—	—	—
Exercise of stock options	241	—	3,722		—	—	3,722
Issuance of shares under the employee stock purchase plan	65	—	2,429		—	—	2,429
Repurchases of common stock for income tax withholding	—	—	(11)		—	—	(11)
Stock-based compensation	—	—	32,341		—	—	32,341
Other comprehensive loss	—	—	—		(140)	—	(140)
Net loss	—	—	—		—	(70,922)	(70,922)
Balances as of March 31, 2025	59,857	$—		$1,753,600		$(662)		$(1,312,830)	$440,108

Commonstock · Additional paid-incapital · Accumulated Othercomprehensiveincome · Accumulateddeficit · Totalstockholders'equity
(In thousands) · Shares · Amount
Balances as of September 30, 2023	57,557	$—		$1,657,222		$(756)		$(1,033,034)	$623,432
Impact of ASU 2016-13 adoption	—	$—		$—		$—		$(148)	$(148)
Vesting of restricted stock units	489	—	—		—	—	—
Exercise of stock options	127	—	2,268		—	—	2,268
Issuance of shares under the employee stock purchase plan	124	—	2,047		—	—	2,047
Repurchases of common stock for income tax withholding	(135)	—	(3,960)		—	—	(3,960)
Stock-based compensation	—	—	24,896		—	—	24,896
Other comprehensive income	—	—	—		96	—	96
Net loss	—	—	—		—	(88,500)	(88,500)
Balances as of March 31, 2024	58,162	$—		$1,682,473		$(660)		$(1,121,682)	$560,131

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.